Loading viewer...
annual_report
Format: PDF annual_report
Acadia Pharmaceuticals reported record 2024 revenues of $957.8 million, up 32% year-over-year, driven by strong performance of NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome. The company strengthened its executive leadership team and outlined a long-term growth strategy focused on its neuroscience and neuro-rare disease franchises with plans to expand globally.
annual_report
Qinetiq Group
presentation
ADP 2017 Annual Meeting Proxy Statement
annual_reportannual_report
116 Pages
Automatic Data Processing
annual_report
Rowan Companies
Ahli United Bank 2023 Annual Report
annual_reportannual_report
74 Pages
Ahli United Bank B.S.C. (c)
annual_report
TCF Bank